Literature DB >> 26837942

Rare extrapulmonary complications of Mycoplasma pneumoniae infection.

Kiran Dhaliwal1, Kevin Enright1.   

Abstract

Stevens-Johnsons syndrome (SJS) is a rare extra-pulmonary complication of Mycoplasma pneumoniae infection. We present the case of a 26-year-old man with fever, cough, extensive oral mucosal ulceration and a widespread truncal rash. He was diagnosed with M. pneumoniae-induced SJS. He responded well to antibiotics and steroids initially, but went on to develop pseudomembranous conjunctivitis requiring bilateral amniotic membrane grafting. SJS is most commonly drug-induced, however, M. pneumoniae is the commonest infectious cause and should be considered in the differential diagnosis. It is also important to get specialist care involved early to minimise the long-term effects of any complications. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26837942      PMCID: PMC4746538          DOI: 10.1136/bcr-2015-214044

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

1.  Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the "gold standard".

Authors:  Matthias F C Beersma; Kristien Dirven; Alje P van Dam; Kate E Templeton; Eric C J Claas; Herman Goossens
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

2.  Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management.

Authors:  Yi-Sheng Chang; Fu-Chin Huang; Sung-Huei Tseng; Chao-Kai Hsu; Chung-Liang Ho; Hamm-Ming Sheu
Journal:  Cornea       Date:  2007-02       Impact factor: 2.651

Review 3.  Mycoplasma pneumoniae-induced cutaneous disease.

Authors:  Peter C Schalock; James G H Dinulos
Journal:  Int J Dermatol       Date:  2009-07       Impact factor: 2.736

Review 4.  Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review.

Authors:  Theresa N Canavan; Erin F Mathes; Ilona Frieden; Kanade Shinkai
Journal:  J Am Acad Dermatol       Date:  2015-02       Impact factor: 11.527

5.  Statistical analysis of Stevens-Johnson syndrome caused by Mycoplasma pneumonia infection in Japan.

Authors:  Yuko Kunimi; Yuko Hirata; Michiko Aihara; Yumiko Yamane; Zenro Ikezawa
Journal:  Allergol Int       Date:  2011-12       Impact factor: 5.836

6.  Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic.

Authors:  David A Wetter; Michael J Camilleri
Journal:  Mayo Clin Proc       Date:  2010-02       Impact factor: 7.616

7.  Erythema multiforme in children. Response to treatment with systemic corticosteroids.

Authors:  J E Rasmussen
Journal:  Br J Dermatol       Date:  1976-08       Impact factor: 9.302

Review 8.  Mycoplasma pneumoniae infections.

Authors:  M R Hammerschlag
Journal:  Curr Opin Infect Dis       Date:  2001-04       Impact factor: 4.915

9.  Comparison of real-time polymerase chain reaction and serological tests for the confirmation of Mycoplasma pneumoniae infection in children with clinical diagnosis of atypical pneumonia.

Authors:  Hsin-Yu Chang; Luan-Yin Chang; Pei-Lan Shao; Ping-Ing Lee; Jong-Min Chen; Chin-Yun Lee; Chun-Yi Lu; Li-Min Huang
Journal:  J Microbiol Immunol Infect       Date:  2013-05-29       Impact factor: 4.399

10.  Mycoplasma pneumoniae with atypical stevens-johnson syndrome: a diagnostic challenge.

Authors:  Ralph Yachoui; Sharon L Kolasinski; David E Feinstein
Journal:  Case Rep Infect Dis       Date:  2013-01-08
View more
  2 in total

1.  Acute Pancreatitis: An Unusual Extrapulmonary Manifestation of Mycoplasma pneumoniae.

Authors:  Hina Rmsha Alfia Khan; Avtar Singh; Omer Usman; Samir Rafiq; Anam Amin
Journal:  Cureus       Date:  2022-05-16

Review 2.  [Clinical implications of the genus Mycoplasma].

Authors:  D Gómez Rufo; E García Sánchez; J E García Sánchez; M García Moro
Journal:  Rev Esp Quimioter       Date:  2021-03-18       Impact factor: 1.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.